New SEC Form D filing

Graviton BioScience Corp, 2026-11-16

A new SEC Form D private-offering notice from New York, NY, a $75,000,000 filer-stated offering target in Biotech. The source filing is one click away.

What this filing says

Graviton BioScience Corp site↗ Verified via SEC Form D

Clinical-stage biotech developing selective ROCK2 inhibitors for fibrotic, autoimmune, and CNS diseases, including GV101 for Friedreich's ataxia.

Filed 3 days agoFiled to raise $75,000,000First money in 2026-10-23Raised so far $5,000,279HQ (as filed) New York, NYSector Biotech web-verified against the company’s own siteStage (inferred) GrowthCall status Delayed filing
Source linked the Form D on EDGAR↗Website verified gravitoncorp.com↗Named in the filing 7 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source